AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12459665 — intervention group
Group type: EXPERIMENTAL
Intervention: IDD-D Propofol (2.5 mg/kg bolus + 0.2 mg/kg/min infusion for 30 min)
Number of subjects: 24
Study 12459665 — intervention group
Group type: EXPERIMENTAL
Intervention: IDD-D Propofol (30-min infusion)
Number of subjects: 24
Study 12459665 — intervention group
Group type: COMPARATOR
Intervention: Diprivan
Number of subjects: 24
Study 12459665 — intervention group
Group type: EXPERIMENTAL
Intervention: IDD-D Propofol
Number of subjects: 24
Study 12459665 — intervention group
Group type: EXPERIMENTAL
Intervention: Both formulations
Number of subjects: 24
Study 10362414 — intervention group
Group type: EXPERIMENTAL
Intervention: Humid‐Vent Filter Light HMEF
Number of subjects: 140
Study 10362414 — intervention group
Group type: COMPARATOR
Intervention: Clear ThermAl HMEF
Number of subjects: 140
Study 7589025 — intervention group
Group type: EXPERIMENTAL
Intervention: Fatty cream 0.1% mometasone furoate (EFC)
Number of subjects: 12
Study 7589025 — intervention group
Group type: COMPARATOR
Intervention: Fatty cream 0.1% hydrocortisone‐17‐butyrate (LLFC)
Number of subjects: 12
Study 7589025 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 12
Study 2248115 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-regulation training (three groups with different intensities)
Number of subjects: 40
Study 7004827 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenclofenac (900 mg daily)
Number of subjects: 30
Study 7004827 — intervention group
Group type: COMPARATOR
Intervention: Indometacin (100 mg daily)
Number of subjects: 30
Study 7004827 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenclofenac
Number of subjects: 30
Study 7004827 — intervention group
Group type: COMPARATOR
Intervention: Indometacin
Number of subjects: 30
Study 31287129 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of muscle relaxant
Number of subjects: 132
Study 31287129 — intervention group
Group type: EXPERIMENTAL
Intervention: Sniffing position
Number of subjects: 132
Study 31287129 — intervention group
Group type: COMPARATOR
Intervention: No muscle relaxant
Number of subjects: 132
Study 31287129 — intervention group
Group type: COMPARATOR
Intervention: Control group (no muscle relaxant)
Number of subjects: 132
Study 28634002 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard treatment + acupressure (AP group)
Number of subjects: 62
Study 28634002 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (ST group)
Number of subjects: 62
Study 28634002 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment + mock acupressure (mock AP group)
Number of subjects: 62
Study 26721913 — intervention group
Group type: EXPERIMENTAL
Intervention: Health literacy
Number of subjects: 575
Study 26721913 — intervention group
Group type: COMPARATOR
Intervention: Age (≥ 65 years)
Number of subjects: 575
Study 24147918 — intervention group
Group type: EXPERIMENTAL
Intervention: Meal provision
Number of subjects: 112
Study 24147918 — intervention group
Group type: COMPARATOR
Intervention: Self‐directed diet
Number of subjects: 112
Study 22137462 — intervention group
Group type: EXPERIMENTAL
Intervention: Rimonabant (20mg/day)
Number of subjects: 0
Study 22137462 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 20662907 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial periodontal treatment
Number of subjects: 136
Study 20662907 — intervention group
Group type: COMPARATOR
Intervention: Control group (no initial periodontal treatment)
Number of subjects: 136
Study 17562236 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic cranial irradiation (PCI)
Number of subjects: 0
Study 16004813 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy combined with surgery (36 patients)
Number of subjects: 68
Study 16004813 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone (32 patients)
Number of subjects: 68
Study 16004813 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy combined with surgery
Number of subjects: 68
Study 10677808 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocolloid patches containing TACA (triamcinolone acetonide)
Number of subjects: 0
Study 10677808 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocolloid patches containing TACA
Number of subjects: 0
Study 9289305 — intervention group
Group type: EXPERIMENTAL
Intervention: Allergovit
Number of subjects: 699
Study 9289305 — intervention group
Group type: COMPARATOR
Intervention: Catalet
Number of subjects: 699
Study 8422849 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine (CBZ)
Number of subjects: 15
Study 8422849 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenytoin (PHT)
Number of subjects: 15
Study 8422849 — intervention group
Group type: COMPARATOR
Intervention: Nondrug conditions
Number of subjects: 15
Study 3790382 — intervention group
Group type: EXPERIMENTAL
Intervention: DDD 100
Number of subjects: 10
Study 3790382 — intervention group
Group type: COMPARATOR
Intervention: VVI
Number of subjects: 10
Study 3790382 — intervention group
Group type: COMPARATOR
Intervention: DDD 150
Number of subjects: 10
Study 30527790 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular treatment (EVT)
Number of subjects: 71
Study 28707567 — intervention group
Group type: EXPERIMENTAL
Intervention: Powerful Together with Diabetes intervention group
Number of subjects: 131
Study 28707567 — intervention group
Group type: COMPARATOR
Intervention: Standard diabetes education (control group)
Number of subjects: 131
Study 25231130 — intervention group
Group type: EXPERIMENTAL
Intervention: Gleason score (GS) categories <3 + 3, 3 + 4, 4 + 3, >4 + 4
Number of subjects: 3282
Study 25231130 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher Gleason scores
Number of subjects: 3282
Study 25231130 — intervention group
Group type: COMPARATOR
Intervention: Biopsy GS from England
Number of subjects: 3282
Study 25231130 — intervention group
Group type: EXPERIMENTAL
Intervention: Gleason score drift
Number of subjects: 3282
Study 22983593 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine 10 μg/kg
Number of subjects: 46
Study 22983593 — intervention group
Group type: COMPARATOR
Intervention: Saline (control group)
Number of subjects: 46
Study 21429067 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin E2 vaginal gel (1 mg/2 mg)
Number of subjects: 165
Study 21429067 — intervention group
Group type: COMPARATOR
Intervention: Prostaglandin E2 vaginal tablets (3 mg)
Number of subjects: 165
Study 19233432 — intervention group
Group type: EXPERIMENTAL
Intervention: Naftopidil 50 mg daily
Number of subjects: 60
Study 19233432 — intervention group
Group type: COMPARATOR
Intervention: Watchful waiting (Control)
Number of subjects: 60
Study 16944044 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) replacement therapy for 24 months
Number of subjects: 10
Study 16944044 — intervention group
Group type: COMPARATOR
Intervention: Control group (no GH replacement)
Number of subjects: 10
Study 12738139 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole (250 mg orally three times per day) and erythromycin (250 mg orally four times per day) for 10 days
Number of subjects: 715
Study 12738139 — intervention group
Group type: COMPARATOR
Intervention: Placebo pills for 10 days
Number of subjects: 715
Study 11033399 — intervention group
Group type: EXPERIMENTAL
Intervention: Silicone IOL
Number of subjects: 240
Study 11033399 — intervention group
Group type: EXPERIMENTAL
Intervention: Acrylic IOL
Number of subjects: 240
Study 11033399 — intervention group
Group type: EXPERIMENTAL
Intervention: PMMA IOL
Number of subjects: 240
Study 9071898 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal therapy (pre‐operative chemotherapy, Patey mastectomy, flap irradiation and adjuvant hormone therapy)
Number of subjects: 108
Study 9071898 — intervention group
Group type: COMPARATOR
Intervention: Initial hormone therapy
Number of subjects: 108
Study 9071898 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal therapy
Number of subjects: 108
Study 9071898 — intervention group
Group type: COMPARATOR
Intervention: Hormone therapy
Number of subjects: 108
Study 8416161 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolrestat (200 mg/d given in the morning)
Number of subjects: 45
Study 8416161 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 3518400 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemalet
Number of subjects: 31
Study 3518400 — intervention group
Group type: COMPARATOR
Intervention: Simplate II
Number of subjects: 31
Study 29764671 — intervention group
Group type: EXPERIMENTAL
Intervention: Subclinical atrial fibrillation (SCAF)
Number of subjects: 44
Study 29764671 — intervention group
Group type: EXPERIMENTAL
Intervention: Subclinical atrial fibrillation (SCAF) detected within 30 days before stroke
Number of subjects: 44
Study 29764671 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with SCAF
Number of subjects: 44
Study 29764671 — intervention group
Group type: COMPARATOR
Intervention: Patients without SCAF
Number of subjects: 44
Study 27992261 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone gel for 14 weeks (TAP)
Number of subjects: 0
Study 27992261 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone gel for 36 months (TEAAM)
Number of subjects: 0
Study 27992261 — intervention group
Group type: COMPARATOR
Intervention: Placebo (TAP)
Number of subjects: 0
Study 27992261 — intervention group
Group type: COMPARATOR
Intervention: Placebo (TEAAM)
Number of subjects: 0
Study 25615959 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher IL-6 levels
Number of subjects: 62
Study 25615959 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher tumor necrosis factor-α levels
Number of subjects: 62
Study 24246619 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative air leak test (ALT)
Number of subjects: 103
Study 24246619 — intervention group
Group type: COMPARATOR
Intervention: Non-ALT
Number of subjects: 103
Study 21135170 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral glucocorticosteroids (GCSs)
Number of subjects: 0
Study 21135170 — intervention group
Group type: EXPERIMENTAL
Intervention: GCS-pretreated LCs
Number of subjects: 0
Study 21135170 — intervention group
Group type: COMPARATOR
Intervention: TGF-β blockage
Number of subjects: 0
Study 21135170 — intervention group
Group type: COMPARATOR
Intervention: Combination of anti-TGF-β and anti-IL-10 Abs
Number of subjects: 0
Study 18973494 — intervention group
Group type: EXPERIMENTAL
Intervention: Early losartan therapy
Number of subjects: 97
Study 18973494 — intervention group
Group type: COMPARATOR
Intervention: Control (no losartan therapy)
Number of subjects: 97
Study 17165637 — intervention group
Group type: EXPERIMENTAL
Intervention: ezetimibe/simvastatin, 10/20 mg/d
Number of subjects: 1229
Study 17165637 — intervention group
Group type: EXPERIMENTAL
Intervention: ezetimibe/simvastatin, 10/40 mg/d
Number of subjects: 1229
Study 17165637 — intervention group
Group type: EXPERIMENTAL
Intervention: ezetimibe/simvastatin
Number of subjects: 1229
Study 17165637 — intervention group
Group type: COMPARATOR
Intervention: atorvastatin
Number of subjects: 1229
Study 12670129 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentagastrin
Number of subjects: 0
Study 12670129 — intervention group
Group type: COMPARATOR
Intervention: Ethinyl estradiol (EE)
Number of subjects: 0
Study 12670129 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 10636613 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate hyperventilation
Number of subjects: 24
Study 10636613 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebrovenous blood temperature monitoring during CPP reduction
Number of subjects: 24
Study 10636613 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebrovenous blood temperature before hyperventilation
Number of subjects: 24
Study 7761882 — intervention group
Group type: EXPERIMENTAL
Intervention: loratadine 10mg daily
Number of subjects: 39
Study 7761882 — intervention group
Group type: COMPARATOR
Intervention: astemizole 10mg daily
Number of subjects: 39
Study 3287943 — intervention group
Group type: EXPERIMENTAL
Intervention: SCH 33861 (topical angiotensin converting enzyme inhibitor)
Number of subjects: 20
Study 3287943 — intervention group
Group type: COMPARATOR
Intervention: Timolol 0.5%
Number of subjects: 20
Study 3287943 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 28688960 — intervention group
Group type: EXPERIMENTAL
Intervention: Massage combined with phototherapy
Number of subjects: 134
Study 28688960 — intervention group
Group type: COMPARATOR
Intervention: Phototherapy only
Number of subjects: 134
Study 26041587 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrin Pad (FP)
Number of subjects: 91
Study 26041587 — intervention group
Group type: COMPARATOR
Intervention: Standard of Care (SoC)
Number of subjects: 91
Study 26041587 — intervention group
Group type: COMPARATOR
Intervention: Fibrin Pad (FP) and Standard of Care (SoC)
Number of subjects: 91
Study 23603517 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated-slip training before encountering a novel, unannounced trip while walking
Number of subjects: 32
Study 23603517 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed training with both types of perturbation (trips and slips)
Number of subjects: 32
Study 23603517 — intervention group
Group type: COMPARATOR
Intervention: Control group (only experienced the novel, unannounced trip)
Number of subjects: 32
Study 21454959 — intervention group
Group type: COMPARATOR
Intervention: nCPAP
Number of subjects: 43
Study 21454959 — intervention group
Group type: EXPERIMENTAL
Intervention: MAD
Number of subjects: 43
Study 19738134 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated infusion of streptokinase
Number of subjects: 120
Study 19738134 — intervention group
Group type: COMPARATOR
Intervention: Conventional infusion of streptokinase
Number of subjects: 120
Study 17692719 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline 1 mg BID
Number of subjects: 250
Study 17692719 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 250
Study 15172407 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan
Number of subjects: 5010
Study 15172407 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5010
Study 11876933 — intervention group
Group type: EXPERIMENTAL
Intervention: CD3AK cells cultured in serum-free medium
Number of subjects: 0
Study 11876933 — intervention group
Group type: COMPARATOR
Intervention: Routine treatment (Control)
Number of subjects: 0
Study 9730797 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytokine measurement (IL-6, TNF-alpha, IFN-gamma) in patients with pneumonia
Number of subjects: 44
Study 9730797 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytokine measurement (IL-6, TNF-alpha, IFN-gamma) in patients with Chlamydia pneumonia
Number of subjects: 44
Study 7756208 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral contraceptives
Number of subjects: 794
Study 7756208 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes
Number of subjects: 794
Study 7756208 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertension
Number of subjects: 794
Study 7756208 — intervention group
Group type: EXPERIMENTAL
Intervention: Migraine
Number of subjects: 794
Study 7756208 — intervention group
Group type: EXPERIMENTAL
Intervention: Previous non-cerebral thrombotic disease
Number of subjects: 794
Study 7756208 — intervention group
Group type: EXPERIMENTAL
Intervention: Other predisposing medical diseases
Number of subjects: 794
Study 2264427 — intervention group
Group type: EXPERIMENTAL
Intervention: Excision and primary closure
Number of subjects: 96
Study 2264427 — intervention group
Group type: COMPARATOR
Intervention: Excision and healing by secondary granulation
Number of subjects: 96
Study 431635 — intervention group
Group type: EXPERIMENTAL
Intervention: Children less than 24 months of age
Number of subjects: 107
Study 431635 — intervention group
Group type: EXPERIMENTAL
Intervention: White children
Number of subjects: 107
Study 31423922 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticoagulation initiated on Day 3
Number of subjects: 1500
Study 31423922 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticoagulation initiated on Day 6
Number of subjects: 1500
Study 31423922 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticoagulation initiated on Day 10
Number of subjects: 1500
Study 31423922 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticoagulation initiated on Day 14
Number of subjects: 1500
Study 31423922 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticoagulation initiated on Day 6 (for severe stroke)
Number of subjects: 1500
Study 31423922 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticoagulation initiated on Day 10 (for severe stroke)
Number of subjects: 1500
Study 31423922 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticoagulation initiated on Day 14 (for severe stroke)
Number of subjects: 1500
Study 31423922 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticoagulation initiated on Day 21 (for severe stroke)
Number of subjects: 1500
Study 28284883 — intervention group
Group type: EXPERIMENTAL
Intervention: Etomidate
Number of subjects: 128
Study 28284883 — intervention group
Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 128
Study 25869025 — intervention group
Group type: EXPERIMENTAL
Intervention: I:E ratio of 1:1
Number of subjects: 80
Study 25869025 — intervention group
Group type: COMPARATOR
Intervention: I:E ratio of 1:2
Number of subjects: 80
Study 23316063 — intervention group
Group type: COMPARATOR
Intervention: Ringer (control)
Number of subjects: 24
Study 23316063 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mM N(G)-nitro-l-arginine methyl ester (l-NAME; NO synthase inhibitor)
Number of subjects: 24
Study 23316063 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mM ketorolac (COX inhibitor)
Number of subjects: 24
Study 23316063 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of l-NAME + ketorolac
Number of subjects: 24
Study 21077801 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose prednisolone (5-7.5 mg) for at least 2 years (P-group)
Number of subjects: 100
Study 21077801 — intervention group
Group type: COMPARATOR
Intervention: No prednisolone treatment (NoP-group)
Number of subjects: 100
Study 21077801 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone treatment
Number of subjects: 100
Study 19808874 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipilimumab at 3 mg/kg and then monthly at 1 mg/kg x 3 months (dose level 1), escalating to 3 mg/kg monthly x 4 months (dose level 2)
Number of subjects: 18
Study 19808874 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Number of subjects: 18
Study 16739319 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraarterial ACNU administration (17 patients)
Number of subjects: 33
Study 16739319 — intervention group
Group type: COMPARATOR
Intervention: Intravenous ACNU administration (16 patients)
Number of subjects: 33
Study 14715359 — intervention group
Group type: EXPERIMENTAL
Intervention: Nesiritide
Number of subjects: 0
Study 14715359 — intervention group
Group type: COMPARATOR
Intervention: High-dose nitroglycerin
Number of subjects: 0
Study 11333081 — intervention group
Group type: EXPERIMENTAL
Intervention: Ingroup
Number of subjects: 258
Study 11333081 — intervention group
Group type: COMPARATOR
Intervention: Outgroup
Number of subjects: 258
Study 9140895 — intervention group
Group type: EXPERIMENTAL
Intervention: URI group (inoculated with HRV 16)
Number of subjects: 55
Study 9140895 — intervention group
Group type: COMPARATOR
Intervention: CRL group (non-infected control)
Number of subjects: 55
Study 7798535 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled beclomethasone dipropionate 500 micrograms twice a day
Number of subjects: 0
Study 7798535 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 3277875 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin E2 vaginal suppositories (2.5 mg PGE2 in Witepsol S55)
Number of subjects: 113
Study 3277875 — intervention group
Group type: COMPARATOR
Intervention: Intracervical prostaglandin gel (1 mg PGE2 in 5 g hydroxypropylmethyl cellulose)
Number of subjects: 113
Study 3277875 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin E2 vaginal suppositories
Number of subjects: 113
Study 3277875 — intervention group
Group type: COMPARATOR
Intervention: Intracervical prostaglandin gel
Number of subjects: 113
Study 30947574 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-port laparoscopic right hemicolectomy (TPLRC)
Number of subjects: 168
Study 30947574 — intervention group
Group type: COMPARATOR
Intervention: Five-port laparoscopic right hemicolectomy (FPLRC)
Number of subjects: 168
Study 29678471 — intervention group
Group type: EXPERIMENTAL
Intervention: Radium-223 (Ra-223) therapy
Number of subjects: 571
Study 29678471 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 571
Study 28774396 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 2305
Study 28774396 — intervention group
Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 2305
Study 26223227 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative pressure wound device
Number of subjects: 300
Study 26223227 — intervention group
Group type: COMPARATOR
Intervention: Standard adhesive gauze dressing
Number of subjects: 300
Study 23837838 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower tidal volumes
Number of subjects: 150
Study 23837838 — intervention group
Group type: COMPARATOR
Intervention: Conventional tidal volumes
Number of subjects: 150
Study 20160637 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic-assisted distal gastrectomy (LADG)
Number of subjects: 342
Study 20160637 — intervention group
Group type: COMPARATOR
Intervention: Open gastrectomy (ODG)
Number of subjects: 342
Study 19055226 — intervention group
Group type: EXPERIMENTAL
Intervention: SLS (dentifrice with SLS)
Number of subjects: 25
Study 16870282 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention
Number of subjects: 126
Study 16870282 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 126
Study 12808010 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral interventions focusing on social support, knowledge, and self-efficacy
Number of subjects: 354
Study 11014375 — intervention group
Group type: EXPERIMENTAL
Intervention: Vasodilator therapy in chronic aortic regurgitation (AR)
Number of subjects: 0
Study 11014375 — intervention group
Group type: EXPERIMENTAL
Intervention: Vasodilator therapy in chronic mitral regurgitation (MR)
Number of subjects: 0